#Drug-Repositioning

2 stories

Research April 13, 2026 · View digest

Nature Medicine Review Maps the Expanding Landscape of GLP-1 Medicines

A comprehensive review by D.J. Drucker in Nature Medicine outlines GLP-1 medicines expanding beyond diabetes and obesity into cardiovascular disease, neurodegenerative disorders, substance use, metabolic liver disease, arthritis, type 1 diabetes, and inflammatory bowel disease. New multi-agonist molecules with optimized pharmacokinetics are producing greater weight loss.

Research March 24, 2026 · View digest

NeurologyLive Review: GLP-1 Drugs Explored for Parkinson's, MS, and Sleep Disorders

A comprehensive NeurologyLive review examines evidence for repositioning GLP-1 drugs across neurological conditions. Exenatide and lixisenatide show motor benefits in Parkinson's disease, while GLP-1 agonists reduced intracranial pressure and migraine days in idiopathic intracranial hypertension. The semaglutide EVOKE trials in Alzheimer's failed clinically despite modest biomarker improvements.